联合王国将启动2026年对16岁以下青少年青春期阻塞者的试验,以评估安全和有效性。 UK to launch 2026 trial on puberty blockers for under-16s to assess safety and effectiveness.

将于2026年1月开始的英国临床试验将研究16岁以下儿童的青春期阻塞器,目的是在对不孕症和大脑发育等长期影响日益关切的情况下评估其安全和有效性。 A UK clinical trial set to begin in January 2026 will study puberty blockers for children under 16, aiming to assess their safety and effectiveness amid growing concerns over long-term impacts like infertility and brain development. 由伦敦国王学院领导,并由监管机构批准,“途径”审判将以保障措施监测身体和情感结果。 Led by King’s College London and approved by regulatory bodies, the Pathways trial will monitor physical and emotional outcomes with safeguards. 包括前病人凯拉·贝尔(Keira Bell)和詹姆斯·埃塞斯(James Esses)在内的批评者认为审判不道德, 质疑儿童的同意能力, Critics, including former patients Keira Bell and James Esses, argue the trial is unethical, questions children’s ability to consent, and risks harm, urging follow-up studies for past patients instead. 政府维持基于证据的护理至关重要,审判必须符合严格的标准。 The government maintains evidence-based care is essential and that the trial meets rigorous standards.